PCA3 score of 20 could improve prostate cancer detection: Results obtained on 734 Italian individuals

被引:14
作者
Capoluongo, Ettore [1 ]
Zambon, Carlo Federico [2 ]
Basso, Daniela [2 ]
Boccia, Stefania [3 ]
Rocchetti, Sandro [1 ]
Leoncini, Emanuele [3 ]
Palumbo, Sara [1 ]
Padoan, Andrea [2 ]
Albino, Giuseppe [1 ]
Todaro, Angelo [4 ]
Prayer-Galetti, Tommaso [4 ]
Zattoni, Filiberto [4 ]
Zuppi, Cecilia [1 ]
Plebani, Mario [2 ]
机构
[1] Univ Cattolica Sacro Cuore, Sch Med, Inst Biochem & Clin Biochem, Lab Clin Mol Biol, I-00168 Rome, Italy
[2] Univ Padua, Dept Lab Med, DIMED, I-35100 Padua, Italy
[3] Univ Cattolica Sacro Cuore Rome, Inst Publ Hlth, Sect Hyg, Rome, Italy
[4] Univ Padua, DiSCOG, Dept Surg Oncol & Gastroenterol Sci, I-35100 Padua, Italy
关键词
PCA3; score; Progensa; PCa; MOLECULAR URINE ASSAY; TUMOR VOLUME; DIAGNOSIS; VALIDATION;
D O I
10.1016/j.cca.2013.10.022
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
100118 [医学信息学]; 100208 [临床检验诊断学];
摘要
Background: The role of PCa3 score in the diagnostics of prostate cancer (PCa) is still under debate, mainly due to the lack of a univocal cut-off useful alone or within nomograms proposed by Urologists. Aim of present study is to compare different PCA3 score cut-off values (20, 25, 35 and 50) observed in 734 patients with suspected PCa who were monitored for about three years with single or multiple biopsies. Methods: 734 patients who underwent first prostate biopsy for suspected PCa were enrolled. One month later the first biopsy result was obtained, both negative and positive PCa patients were investigated by means of PCA3 score, in order to establish risk of PCa presence on repeated biopsies. Results: PCA3 score was significantly higher (p < 0.001) in PCa patients to the PCa negative ones, while tPSA did not significantly vary. The best negative predictive value (NPV 97.5%) and sensitivity (95.4%) result were obtained when a PCA3 score of 20 was used. At cut-off value of 50, the 75% of patients resulted as false positive. Conclusions: PCA3 score of 20 could be safely introduced in the prostate cancer screening diagnostic flow chart, since it provides important information regarding the outcome of re-biopsy. (C) 2013 Elsevier B.V. All rights reserved.
引用
收藏
页码:46 / 50
页数:5
相关论文
共 25 条
[1]
PCA3 Molecular Urine Test for Predicting Repeat Prostate Biopsy Outcome in Populations at Risk: Validation in the Placebo Arm of the Dutasteride REDUCE Trial [J].
Aubin, Sheila M. J. ;
Reid, Jennifer ;
Sarno, Mark J. ;
Blase, Amy ;
Aussie, Jacqueline ;
Rittenhouse, Harry ;
Rittmaster, Roger ;
Andriole, Gerald L. ;
Groskopf, Jack .
JOURNAL OF UROLOGY, 2010, 184 (05) :1947-1952
[2]
Relationship between prostate cancer gene 3 (PCA3) and characteristics of tumor aggressiveness [J].
Augustin, Herbert ;
Mayrhofer, Katrin ;
Pummer, Karl ;
Mannweiler, Sebastian .
PROSTATE, 2013, 73 (02) :203-210
[3]
Critical Assessment of Preoperative Urinary Prostate Cancer Antigen 3 on the Accuracy of Prostate Cancer Staging [J].
Auprich, Marco ;
Chun, Felix K. -H. ;
Ward, John F. ;
Pummer, Karl ;
Babaian, Richard ;
Augustin, Herbert ;
Luger, Ferdinand ;
Gutschi, Stefan ;
Budaeus, Lars ;
Fisch, Margit ;
Huland, Hartwig ;
Graefen, Markus ;
Haese, Alexander .
EUROPEAN UROLOGY, 2011, 59 (01) :96-105
[4]
External Validation of Urinary PCA3-Based Nomograms to Individually Predict Prostate Biopsy Outcome [J].
Auprich, Marco ;
Haese, Alexander ;
Walz, Jochen ;
Pummer, Karl ;
de la Taille, Alexandre ;
Graefen, Markus ;
de Reijke, Theo ;
Fisch, Margit ;
Kil, Paul ;
Gontero, Paolo ;
Irani, Jacques ;
Chun, Felix K. -H. .
EUROPEAN UROLOGY, 2010, 58 (05) :727-732
[5]
Barbera Michele, 2012, Arch Ital Urol Androl, V84, P227
[6]
Bradley LA, 2013, J UROLOGY, DOI DOI 10.1016/JJUR0.2013.02.005
[7]
Active surveillance for early-stage prostate cancer - Review of the current literature [J].
Dall'Era, Marc A. ;
Cooperberg, Matthew R. ;
Chan, June M. ;
Davies, Benjamin J. ;
Albertsen, Peter C. ;
Klotz, Laurence H. ;
Warlick, Christopher A. ;
Holmberg, Lars ;
Bailey, Donald E., Jr. ;
Wallace, Meredith E. ;
Kantoff, Philip W. ;
Carroll, Peter R. .
CANCER, 2008, 112 (08) :1650-1659
[8]
Clinical Evaluation of the PCA3 Assay in Guiding Initial Biopsy Decisions [J].
de la Taille, Alexandre ;
Irani, Jacques ;
Graefen, Markus ;
Chun, Felix ;
de Reijke, Theo ;
Kil, Paul ;
Gontero, Paolo ;
Mottaz, Alain ;
Haese, Alexander .
JOURNAL OF UROLOGY, 2011, 185 (06) :2119-2125
[9]
PCA3: A molecular urine assay for predicting prostate biopsy outcome [J].
Deras, Ina L. ;
Aubin, Sheila M. J. ;
Blase, Amy ;
Day, John R. ;
Koo, Seongjoon ;
Partin, Alan W. ;
Ellis, William J. ;
Marks, Leonard S. ;
Fradet, Yves ;
Rittenhouse, Harry ;
Groskopf, Jack .
JOURNAL OF UROLOGY, 2008, 179 (04) :1587-1592
[10]
Predicting prostate biopsy outcome: prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers [J].
Ferro, Matteo ;
Bruzzese, Dario ;
Perdona, Sisto ;
Mazzarella, Claudia ;
Marino, Ada ;
Sorrentino, Alessandra ;
Di Carlo, Angelina ;
Autorino, Riccardo ;
Di Lorenzo, Giuseppe ;
Buonerba, Carlo ;
Altieri, Vincenzo ;
Mariano, Angela ;
Macchia, Vincenzo ;
Terracciano, Daniela .
CLINICA CHIMICA ACTA, 2012, 413 (15-16) :1274-1278